Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$166.19 USD

166.19
636,152

+2.02 (1.23%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Insulet Receives FDA Approval for ACE Pump Implementation

FDA's approval will enable Insulet (PODD) to boost its insulin management business.

Why Is Insulet (PODD) Up 17.3% Since Last Earnings Report?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Insulet (PODD) Scales 52-Week High: What's Driving the Stock?

Insulet (PODD) has various favorable factors to maintain the current high.

Insulet (PODD) Catches Eye: Stock Jumps 8.9%

Insulet (PODD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Here's Why You Should Hold Onto Insulet (PODD) Stock for Now

Investor confidence continues to be high on Insulet's (PODD) solid prospects.

Insulet (PODD) Misses on Q2 Earnings, Ups '19 Revenue View

The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.

Insulet (PODD) Q2 Earnings Lag Estimates

Insulet (PODD) delivered earnings and revenue surprises of -33.33% and 8.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insulet (PODD) Soars to 52-Week High, Time to Cash Out?

Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Insulet (PODD) Hits 52-Week High on Solid Growth Prospects

Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.

Insulet (PODD) Up 27.8% Since Last Earnings Report: Can It Continue?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Insulet (PODD) Beats Earnings and Revenue Estimates in Q1

Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.

Insulet (PODD) Q1 Earnings and Revenues Beat Estimates

Insulet (PODD) delivered earnings and revenue surprises of 250.00% and 3.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Why the Earnings Surprise Streak Could Continue for Insulet (PODD)

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Insulet (PODD) Up 5.1% Since Last Earnings Report?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Insulet (PODD) Beats Earnings and Revenue Estimates in Q4

The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.

Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insulet Gains on Omnipod Reimbursement Update, Rivalry Stiff

Insulet Corporation (PODD) continues to expand Omnipod's market access on growing reimbursements. The company operates in a highly competitive environment.

Insulet (PODD) Down 6.9% Since Last Earnings Report: Can It Rebound?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What's in Store for GW Pharma (GWPH) This Earnings Season?

On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.

Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified

Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.

Insulet (PODD) Beats Earnings and Revenue Estimates in Q3

We are encouraged by the year-over-year improvement in Insulet's (PODD) Q3 results on solid uptake of Omnipod system in the United States. It is also gaining from pursuing direct European operations.

Insulet (PODD) Q3 Earnings and Revenues Top Estimates

Insulet (PODD) delivered earnings and revenue surprises of 50.00% and 1.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?